Feng Zhang (R) with Aera Therapeutics CEO Akin Akinc (Aera)
'Rare outliers': Feng Zhang eyes a new path to genetic medicine delivery with ex-Alnylam leaders and $193M
Marquee CRISPR scientist Feng Zhang, two-decade Alnylam oncology head Akin Akinc and seasoned biotech guru John Maraganore have come together for a new bet …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.